Development
Vera Therapeutics, Inc.
VERA
$20.64
$0.190.93%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -20.10M | -20.16M | -30.07M | -32.44M | -24.68M |
| Total Depreciation and Amortization | -1.44M | -971.00K | -506.00K | -597.00K | -152.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.49M | 3.28M | 3.25M | 3.34M | 6.88M |
| Change in Net Operating Assets | -4.91M | 86.00K | 1.04M | 8.54M | -465.00K |
| Cash from Operations | -22.97M | -17.77M | -26.29M | -21.16M | -18.42M |
| Capital Expenditure | -- | -- | -- | 0.00 | -38.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 16.23M | -86.45M | 12.23M | 13.44M | -2.40M |
| Cash from Investing | 16.23M | -86.45M | 12.23M | 13.44M | -2.44M |
| Total Debt Issued | -- | -- | -- | 19.82M | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 297.00K | 432.00K | 115.24M | 826.00K | 976.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | -7.26M | 67.00K | -68.00K |
| Cash from Financing | 297.00K | 432.00K | 107.98M | 20.71M | 908.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6.45M | -103.79M | 93.93M | 12.98M | -19.95M |